The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Eli Lilly ( LLY 1.07%) and Novo Nordisk ( NVO -1.99%) are two of the most valuable healthcare stocks in the world, largely ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

According to market research firm GlobalData on the 2nd (local time), Eli Lilly's obesity drug Zepbound is projected to quickly surpass Novo Nordisk's Wegovy in market share and dominate the ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Additionally, Lilly closed out the year by snagging a key new approval for Zepbound in obstructive sleep apnea (OSA), making ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...